Series C Investment by MVM Partners LLP and Sofinnova Partners SAS in Neurent Medical Limited

Byrne Wallace Shields LLP is pleased to have acted for MVM Partners LLP and Sofinnova Partners SAS in relation to the Series C fundraising in Neurent Medical Limited to advance the development of NEUROMARK, a posterior nasal nerve ablation that provides relief against chronic rhinitis. 
 
The financing was led by MVM Partners, with significant participation from Sofinnova Partners, and included continued support from existing investors EQT Life Sciences, Atlantic Bridge, Fountain Healthcare Partners and Enterprise Ireland.
 
The Byrne Wallace Shields LLP team who advised on this transaction included Catherine Dowling (Partner, Corporate & Life Sciences), Catherine Cusack (Managing Associate, Corporate & Life Sciences) and Alban O’Callaghan (Managing Associate, Corporate).
 
For further information please click here.